- Trials with a EudraCT protocol (110)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
110 result(s) found for: Electrophoresis.
Displaying page 1 of 6.
EudraCT Number: 2014-000268-17 | Sponsor Protocol Number: CC-4047-MM-007 | Start Date*: 2015-04-02 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJEC... | |||||||||||||
Medical condition: relapsed or refractory multiple myeloma (MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NO (Completed) DK (Completed) SE (Completed) FI (Completed) ES (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003275-12 | Sponsor Protocol Number: AZI/SCAND/01 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Copenhagen CF-centre | |||||||||||||
Full Title: Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprof... | |||||||||||||
Medical condition: Cystic fibrosis with intermittent colonization of the airways with pseudomonas aeruginosa. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NO (Ongoing) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003517-95 | Sponsor Protocol Number: OP-103 | Start Date*: 2017-01-31 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to... | |||||||||||||
Medical condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Temporarily Halted) BE (Completed) DK (Completed) NL (Completed) NO (Completed) FR (Ongoing) PL (Completed) AT (Completed) EE (Completed) LT (Completed) IT (Ongoing) RO (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000431-49 | Sponsor Protocol Number: CC220MM002 | Start Date*: 2021-10-18 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Ongoing) PT (Ongoing) FI (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) GR (Ongoing) IE (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021146-22 | Sponsor Protocol Number: 5339 | Start Date*: 2012-10-23 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Alemtuzumab and rheumatoid arthritis - an immunisation study | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004664-18 | Sponsor Protocol Number: NEOD001-OLE251 | Start Date*: 2017-08-08 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO) | |||||||||||||
Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004835-30 | Sponsor Protocol Number: CAD5 | Start Date*: 2012-10-23 |
Sponsor Name:Department of Medicine, Haugesund Hospital | ||
Full Title: Therapy for chronic cold agglutinin disease: A prospective, non-randomized international multicenter trial on the safety and efficacy of bendamustine and rituximab combination therapy. | ||
Medical condition: Primary chronic cold agglutinin disease requiring treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001563-21 | Sponsor Protocol Number: IM-T-hLL2-18 | Start Date*: 2005-02-02 |
Sponsor Name:Immunomedics, Inc. | ||
Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016096-29 | Sponsor Protocol Number: 08/0183 | Start Date*: 2010-03-05 |
Sponsor Name:University College London [...] | ||
Full Title: Pilot of oral Sildenafil for the treatment of Pulmonary Hypertension in Thalassaemia with comparison to controls. | ||
Medical condition: Pulmonary Hypertension in Thalassaemia patients | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005384-16 | Sponsor Protocol Number: FLORAMICAR | Start Date*: 2016-04-26 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl... | ||||||||||||||||||
Medical condition: Patients with high clinical suspicion of cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004190-46 | Sponsor Protocol Number: D5136C00013 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients A... | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001737-27 | Sponsor Protocol Number: 54767414AMY3001 | Start Date*: 2018-04-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos... | |||||||||||||
Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) SE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003212-36 | Sponsor Protocol Number: ACE-WM-001 | Start Date*: 2014-12-09 | ||||||||||||||||
Sponsor Name:Acerta Pharma BV | ||||||||||||||||||
Full Title: An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia | ||||||||||||||||||
Medical condition: Waldenström Macroglobulinemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) GR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001052-39 | Sponsor Protocol Number: ARRAY-520-311 | Start Date*: 2014-11-02 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus ... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002161-36 | Sponsor Protocol Number: OP-108 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma | |||||||||||||
Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001023-38 | Sponsor Protocol Number: bb2121-MM-003 | Start Date*: 2019-05-13 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (... | ||||||||||||||||||
Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) DE (Ongoing) BE (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000254-64 | Sponsor Protocol Number: 114056 | Start Date*: 2012-04-12 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell... | ||||||||||||||||||
Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children from 8 weeks up to 2 years of age. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006050-10 | Sponsor Protocol Number: 26866138-MMY-2043 | Start Date*: 2007-09-18 |
Sponsor Name:Janssen-Cilag International, N.V.Turnhoutseweg 30, 2340 Beerse, Belgium | ||
Full Title: A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untre... | ||
Medical condition: Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) AT (Completed) HU (Completed) PT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001957-30 | Sponsor Protocol Number: CA057-001 | Start Date*: 2022-09-22 |
Sponsor Name:Celgene Corporation | ||
Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib And Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Rel... | ||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) AT (Ongoing) IE (Ongoing) PT (Ongoing) FI (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006037-13 | Sponsor Protocol Number: AC-003-IT | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: amyloidosis AL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.